Venlafaxine Hydrochloride Tablet, Extended Release
Product Images NDC 31722-124

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 31722-124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150mg 30s

Label for Venlafaxine Extended-Release Tablets 150 mg by Camber Pharmaceuticals, Inc. The label includes the NDC number 31722-125-30, barcode, and states the package contains 30 tablets. It specifies the drug is prescription-only and includes storage instructions, manufacturer, and medication guide information.*

FDA Label Image

150mg 90s

Label for Venlafaxine Extended-Release Tablets 150 mg by Camber Pharmaceuticals, Inc. This prescription drug label states a 90-tablet count, includes storage instructions, medication guide info, and manufacturer details, featuring a barcode and NDC 31722-125-90.*

FDA Label Image

225mg 30s

Label for Venlafaxine Extended-Release Tablets, 225 mg strength, oral tablet form by Camber Pharmaceuticals, Inc. The label shows dosage strength, quantity of 30 tablets, barcode, storage instructions, and manufacturer information. It includes a note for dispensers to provide the medication guide to patients with each dispense.*

FDA Label Image

225mg 90s

Label for Venlafaxine Extended-Release Tablets 225 mg by Camber Pharmaceuticals, Inc. The label states the product contains 90 tablets and is Rx only. It includes storage instructions, dosage form as extended-release tablets, and notes to the authorized dispenser to provide the attached Medication Guide. Manufacturer details for Ascent Pharmaceuticals, Inc. and Camber Pharmaceuticals, Inc. are also listed.*

FDA Label Image

37.5mg 30s

Label for Venlafaxine Extended-Release Tablets, 37.5 mg strength, oral extended-release tablet form, by Camber Pharmaceuticals, Inc. The label includes NDC 31722-123-30, a 30-tablet count, storage instructions, and manufacturer information for Ascent Pharmaceuticals, Inc. and Camber Pharmaceuticals, Inc.*

FDA Label Image

37.5mg 90s

Packaging label for Venlafaxine Extended-Release Tablets 37.5 mg by Camber Pharmaceuticals, Inc. The label indicates 90 tablets in the package. It includes dosage form (extended-release tablet), strength (37.5 mg), and storage instructions. The label also features the NDC number 31722-123-90 and manufacturer information for Ascent Pharmaceuticals, Inc. and Camber Pharmaceuticals, Inc.*

FDA Label Image

75mg 30s

Label for Venlafaxine Extended-Release Tablets 75 mg by Camber Pharmaceuticals, Inc. The label states the tablet strength as 75 mg, dosage form as extended-release tablets, and package contains 30 tablets. It includes storage instructions, manufacturer details (Ascent Pharmaceuticals, Inc. and Camber Pharmaceuticals, Inc.), dosage guidance to see package insert, and a medication guide URL.*

FDA Label Image

75mg 90s

Label for Venlafaxine Extended-Release Tablets 75 mg by Camber Pharmaceuticals, Inc. The label states the product contains 90 tablets and is for prescription use only. It includes storage instructions, dosage information advising once-daily use, and mentions an attached Medication Guide. The label also lists the manufacturer as Ascent Pharmaceuticals, Inc., Central Islip, NY, and the labeler as Camber Pharmaceuticals, Piscataway, NJ.*

FDA Label Image

Tab1

Data table titled 'Table 1' showing the drug-placebo difference in number of cases of suicidality per 1000 patients treated with venlafaxine. It presents increased cases in patients under 18 and ages 18-24, and decreased cases in those aged 25-64 and 65 or older compared to placebo.*

FDA Label Image

Tab2 And 3

Two data tables presenting study results for venlafaxine hydrochloride. Table 2 shows the number and percentage of sustained elevations in systolic blood pressure (SDBP) in venlafaxine hydrochloride extended-release capsule premarketing studies by indication for major depressive disorder and other clinical trials. Table 3 lists the incidence percentages of sustained SDBP elevations in venlafaxine hydrochloride immediate-release tablet studies by daily dosage ranges (<100 mg, >100 to ≤200 mg, >200 to ≤300 mg, >300 mg).*

FDA Label Image

Tab4

A data table titled 'Final On-Therapy Mean Changes from Baseline in Supine Systolic and Diastolic Blood Pressure (mm Hg) Results by Indication, Study Duration, and Dose in Placebo-Controlled Trials' showing changes in blood pressure for venlafaxine hydrochloride extended-release capsules and placebo. It compares systolic and diastolic blood pressure changes for doses ≤75 mg/day and >75 mg/day across major depressive disorder (8-12 weeks) and other clinical trials (12 weeks).*

FDA Label Image

Tab5

A data table titled 'Incidence of Insomnia and Nervousness in Placebo-Controlled Major Depressive Disorder and Other Trials' comparing the percentages of insomnia and nervousness symptoms reported in patients using Venlafaxine Hydrochloride Extended-Release Capsules versus placebo, across Major Depressive Disorder (n=357 vs n=285) and other trial groups (N=819 vs n=695).*

FDA Label Image

Tab6

A table showing treatment-emergent adverse reaction incidence in short-term placebo-controlled clinical trials comparing Venlafaxine Hydrochloride Extended-Release Capsules and placebo in patients with Major Depressive Disorder. It details the percentage of reported reactions across various body systems including cardiovascular, digestive, nervous system, respiratory, skin, special senses, and urogenital system for both Venlafaxine (n=357) and placebo (n=285) groups.*

FDA Label Image

Tab7

A data table showing treatment-emergent adverse reaction incidence percentages in short-term placebo-controlled clinical trials for venlafaxine hydrochloride extended-release capsules compared to placebo in social anxiety disorder patients. It lists adverse reactions across body systems, including nervous, digestive, cardiovascular, respiratory, and others, with respective incidence rates for venlafaxine and placebo groups.*

FDA Label Image

Structure

Chemical structure of venlafaxine hydrochloride showing its molecular components, including aromatic rings, hydroxyl group, and dimethylamino group, labeled with the compound name at the bottom.*

FDA Label Image

Symptoms Med Guide

A text panel listing warnings or symptoms of concern associated with medication use, including thoughts about suicide or dying, attempts to commit suicide, worsening depression or anxiety, agitation, panic attacks, insomnia, irritability, aggressive behavior, acting on dangerous impulses, mania, unusual mood changes, and visual problems such as eye pain, vision changes, or swelling/redness around the eye.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.